January 8, 2018 / 12:26 PM / a year ago

Axovant to scrap intepirdine program after dementia trial fails

Jan 8 (Reuters) - Axovant Sciences Ltd said on Monday it would discontinue its intepirdine program after the experimental treatment failed in a mid-stage study on patients suffering from a type of dementia.

Neither of the two doses of intepirdine given to patients with dementia with Lewy bodies resulted in improving their motor function, compared with patients given a placebo, Axovant said.

In September, Axovant stopped testing the drug on patients suffering from Alzheimer's after a late-stage trial failure. (Reporting by Tamara Mathias in Bengaluru; Editing by Savio D'Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below